NCT04379011View on ClinicalTrials.gov

Brivaracetam to Reduce Neuropathic Pain in Chronic Spinal Cord Injury

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

February 1, 2021

Primary Completion Date

March 31, 2024

Study Completion Date

September 1, 2024

Conditions
Spinal Cord Injuries
Interventions
DRUG

Brivaracetam

Escalating brivaracetam dose to 150 mg twice daily for 3 months

OTHER

Placebo

Placebo twice daily for 3 months

Trial Locations (2)

55455

University of Minnesota School of Medicine, Minneapolis

80113

Swedish Hospital, Englewood

All Listed Sponsors
lead

University of Minnesota

OTHER

NCT04379011 - Brivaracetam to Reduce Neuropathic Pain in Chronic Spinal Cord Injury | Biotech Hunter | Biotech Hunter